Contrast-enhanced MRI for Liver Lesions

Recruiting in Palo Alto (17 mi)

Overseen byJanio Szklaruk, MD, PHD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.

Research Team

Janio Szklaruk, MD, PHD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for people who've had an abdominal MRI within the last 3 months and have a kidney function score (eGFR) of 30 or above. It's open to any disease type, but not for those with poor kidney function, allergies to IV contrast, pregnant women, or individuals with certain metal implants.

Inclusion Criteria

My condition does not limit my eligibility based on disease type.

Patients with the most recent abdominal magnetic resonance (MR) study obtained within 3 months +/- 1 week

My kidney function is at a safe level for the trial.

Exclusion Criteria

My kidney function is low (eGFR < 30).

I am allergic to or cannot have IV contrast.

Pregnant women

See 1 more

Treatment Details

Interventions

Gadobutrol (Contrast Agent)
Gadoxetate Disodium (Contrast Agent)

Trial OverviewThe study is testing how well contrast-enhanced MRI can spot liver lesions that are either benign (not cancer) or malignant (cancer). It uses two types of contrast agents - gadobutrol and gadoxetate disodium - to improve image clarity and assist in diagnosis.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Diagnostic (contrast-enhanced MRI)Experimental Treatment3 Interventions

Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.